Section 4: Clinical Pharmacy Services

4CPS-242

HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT

4CPS-217

CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS

4CPS-214

EXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS

4CPS-209

Benefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System

4CPS-206​

RIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY

4CPS-182

INCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC

4CPS-172

POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL

4CPS-154

STEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE

4CPS-152

CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING

4CPS-126

REAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS

4CPS-106

SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

4CPS-062

RITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME

4CPS-046

CARDIOVASCULAR RISK OF HIV PATIENTS

4CPS-042

PHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS

4CPS-040

INTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS

Pages